ChromaDex Corp., the global scientific authority on nicotinamide adenine dinucleotide (NAD) and nicotinamide riboside (NR) science, announced the initiation of a first-of-its-kind Phase 1 clinical study sponsored by the University of Florida, in collaboration with the National Institute on Aging. This trial will assess the potential of NIAGEN® (NR) to enhance the effects of exercise … Continue reading First-of-Its-Kind Clinical Study Initiated to Investigate Potential Benefits of Nicotinamide Riboside Combined With Exercise in Older Adults With Hypertension